Results 61 to 70 of about 6,305 (206)

Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer

Nature Communications, 2018
One of the major obstacles in nanoparticle-based therapy is to achieve tumour targeting, limiting non-specific accumulation of the nanoparticles. Here the authors propose the conjugation of anti-HER2 scFv fragments to the silica nanoparticles, increasing
Feng Chen, Kai Ma, Brian Madajewski, Li Zhuang, Li Zhang, Keith Rickert, Marcello Marelli, Barney Yoo, Melik Z. Turker, Michael Overholtzer, Thomas P. Quinn, Mithat Gonen, Pat Zanzonico, Anthony Tuesca, Michael A. Bowen, Larry Norton, J. Anand Subramony, Ulrich Wiesner, Michelle S. Bradbury   +18 more
doaj   +1 more source

Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo

Pharmaceuticals, 2018
Girentuximab (cG250) targets carbonic anhydrase IX (CAIX), a protein which is expressed on the surface of most renal cancer cells (RCCs). cG250 labeled with 177Lu has been used in clinical trials for radioimmunotherapy (RIT) of RCCs.
Tais Basaco, Stefanie Pektor, Josue M. Bermudez, Niurka Meneses, Manfred Heller, José A. Galván, Kayluz F. Boligán, Stefan Schürch, Stephan von Gunten, Andreas Türler, Matthias Miederer   +10 more
doaj   +1 more source

An Overview of Emerging Trends in Targeted Therapy of Triple‐Negative Breast Cancer

International Journal of Breast Cancer, Volume 2026, Issue 1, 2026.
Triple‐negative breast cancer (TNBC) is a biologically diverse, highly aggressive class of breast cancer defined by the absence of estrogen, progesterone, and HER2 receptors. It accounts for approximately 10%–20% of all invasive breast cancers, and disproportionately affects women of younger ages and from minority groups.
Anuj Kumar, Suresh Subramanian, V. Ganesh   +2 more
wiley   +1 more source

Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma

Toxins
Sarcomas are very complex and clinically challenging mesenchymal tumors. Although the standard therapeutic approach has improved the 5-year survival rate, many patients experience local relapses and/or distant metastases.
Giulia Calafato, Massimo Bortolotti, Letizia Polito, Andrea Bolognesi   +3 more
doaj   +1 more source

Novel Bioconjugate Materials: Synthesis, Characterization and Medical Applications

Advanced Healthcare Materials, Volume 14, Issue 31, December 8, 2025.
This review discusses the bioconjugation of novel materials grouped under “biological”, “hybrid” and “synthetic” categories. Medical applications ranging from cancer therapy and diagnostics to optogenetics and tissue engineering are explored, and conjugation trends are highlighted as a general guide. The review concludes with a comparison of techniques
Ellie Martin, Sean P. Doidge, Eiman Aleem, Suela Kellici, Steven Dunn, Claire Atkinson, Philip D. Howes   +6 more
wiley   +1 more source

immunoconjugate

Citation: 'immunoconjugate' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13279 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
REIS E SOUSA CAETANO, SCHULZ OLIVER
openaire   +3 more sources

Individually Specified Drug Immunoconjugates in Cancer Treatment

The International Journal of Biological Markers, 1989
Forty-three patients with disseminated refractory malignancies each received an individually-specified combination of either Adriamycin (24 patients) or mitomycin-C (19 patients) conjugated murine monoclonal antibodies. Tumors were typed using a panel of
R.K. Oldham, M. Lewis, D.W. Orr, S-K. Liao, J.R. Ogden, W.H. Hubbard, R. Birch   +6 more
doaj   +1 more source

Inter‐Nanoparticle FRET for Biosensing: Photophysics Versus Size

Angewandte Chemie International Edition, Volume 64, Issue 39, September 22, 2025.
Förster resonance energy transfer (FRET) systems with luminescent nanoparticles (NPs) as donors and acceptors (inter‐NP FRET) combine unique photophysical properties with large sizes. This review discusses the influence of NP type, architecture, surface chemistry, and optical properties on FRET and the pros and cons of inter‐NP FRET for bioanalytical ...
Eduard Madirov, Clara Catros, Niko Hildebrandt, Chloé Grazon   +3 more
wiley   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non‐Toxic Treatment Option for Superficial Triple Negative Breast Cancer

Cancer Medicine, Volume 14, Issue 18, September 2025.
ABSTRACT Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking estrogen (ER), progesterone (PR), and human epidermal growth factor receptor (HER‐2) expression. It disproportionately affects women of African descent and has a poor clinical prognosis attributed to its acute heterogeneity, thereby causing elevated ...
Fleury Augustin Nsole Biteghe, Neelakshi Mungra, Zaria Malindi, Nyangone Ekome Toung Chalomie, Ketum Ateh Stanislas, Sayeda Yasmin‐Karim, G. Mike Makrigiorgos, Fallon Ester Chipidza, Olusiji Alex Akinrinmade, Srinivas Sridhar, Stefan Barth, Wilfred Ngwa   +11 more
wiley   +1 more source